GC Medical Science Corporation (142280.KQ)
KOSDAQ · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩3,280 (+0.92%) as of
Key statistics
- Market cap
- 78.60B
- Dividend yield
- 0.00%
- 52-week range
- 2,200.00 – 6,660.00
- Beta
- 0.71
- Revenue (TTM)
- 102.16B
- Profit margin
- -2.12%
- Volume
- 599.93k
About GC Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer for cholesterol. The company also offers Covid-19 and flu diagnosis equipment including GENEDIA W Covid-19 Ag, GreenCare FLU2 Influenza A&B Ag, and GENEDIA W Covid-19 & Flu A&B Ag. Additionally, it offers dengue diagnosis equipment including GENEDIA W Dengue NS1 Ag, GENEDIA W Dengue lgM/lgG Ab, and GENEDIA W Dengue NS1 & lgM/lgG Combo. Further, the company provides vet healthcare products, such as CERA-PET blood glucose monitoring system for diabetes; and CERA-PET Multi for non-communicable diseases diagnosis. The company was formerly known as Green Cross Medical Science Corporation and changed its name to GC Medical Science Corporation in May 2026. GC Medical Science Corporation was founded in 1972 and is headquartered in Yongin-Si, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Yongin-Si, South Korea
- Employees
- 134
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.